Schering-Plough Corp

2000 Galloping Hill Road
Kenilworth, NJ 07033

USA

Phone: (908) 298-4000
Fax: (908) 298-7082
Web Site: http://www.schering-plough.com/

A. Company Profile

Schering-Plough (NYSE: SGP) is one of world's leading pharmaceutical companies. The company's product portfolio includes innovative treatments across a wide range of therapeutic areas. There are extensive discovery and development programs in the field of oncology at Schering-Plough.

B. Products

Product Pipelines

1. Doxorubicin

Doxorubicin (adriamycin) is an anthracycline antibiotics. It attacks tumors cells by intercalating with cellular DNA, binding to cell membranes, and generating of oxygen radicals through lipid peroxidation.

2. Ethyol

Ethyol (amifostine) is a selective cytoprotective agent used to reduce toxicities associated with certain cancer chemotherapy and radiotherapy. Specifically, Ethyol is an intravenous organic thiophosphate cytoprotective agent indicated for the reduction of cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer or non-small cell lung cancer (NSCLC). Ethyol is also indicated to reduce the incidence of moderate to severe xerostomia (chronic dry mouth) in patients undergoing post-operative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands.

3. Sarasar

Sarasar (lonafarnib; SCH66336) is a farnesyl transferase inhibitor.

4. Temodar

Temodar contains temozolomide, an imidazotetrazine derivative.